H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Carisma Therapeutics to $9 from $11 and keeps a Buy rating on the shares following the Q4 report. The company announced a strategic shift in pipeline priorities and certain changes in ongoing program efforts, the analyst tells investors in a research note. The firm says the most important update is is CT-0508 will be discontinued in favor of CT-0525 development.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM: